A newly designed radiation therapy protocol in combination with prednisolone as treatment for meningoencephalitis of unknown origin in dogs: a prospective pilot study introducing magnetic resonance spectroscopy as monitor tool by Beckmann, Katrin Melanie
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2015
A newly designed radiation therapy protocol in combination with
prednisolone as treatment for meningoencephalitis of unknown origin in dogs
: a prospective pilot study introducing magnetic resonance spectroscopy as
monitor tool
Beckmann, Katrin Melanie
Abstract: treatment for meningoencephalitis of unknown origin in dogs: a prospective pilot study in-
troducing magnetic resonance spectroscopy as monitor tool Katrin Beckmann1*, Inés Carrera2,3, Frank
Steffen1, Lorenzo Golini1, Patrick R Kircher2, Uwe Schneider4,5, Carla Rohrer Bley4 1 Division of Neu-
rology, Clinic for Small Animal Surgery, Vetsuisse Faculty, University of Zurich, Winterthurerstrasse 260,
CH-8057 Zurich, Switzerland 2 Division of Diagnostic Imaging, Vetsuisse Faculty, University of Zurich,
Winterthurerstrasse 260, CH-8057 Zurich, Switzerland 3 Graduate School for Cellular and Biomedical
Sciences, University of Bern, Switzerland 4 Division of Radiation Oncology, Vetsuisse Faculty, Univer-
sity of Zurich, Winterthurerstrasse 260, CH-8057 Zurich, Switzerland 5 Radiotherapy Hirslanden AG,
Institute for Radiotherapy, Witellikerstrasse 40, CH-8032 Zurich, Switzerland Summary A plethora of
treatment options have been described for canine meningoencephalitis of unknown origin (MUO), yet a
gold standard has not been established. The aim of this prospective pilot study was to document the
effect of a newly designed 30 Gray (Gy) radiation therapy (RT) protocol plus corticosteroids as treatment
for focal and multifocal MUO, to monitor clinical and imaging changes during the course of the disease
with conventional magnetic resonance imaging (MRI) and proton MR Spectroscopy (H-1 MRS) and to
detect the occurrence of radiation related side effects. Six dogs (3 with focal and 3 with multifocal lesions)
were included in the study. The RT protocol used consisted of 30 Gy in 10 fractions. The neurological
status of all six dogs improved during RT, with 3 of 6 cases returning to a normal condition. One dog was
euthanized early during follow-up (<3 weeks after end of RT). Three month follow up MRI was normal
in one dog and improved in 3 dogs and H-1 MRS normalized in 4. In the dog without improvement of
the MRI lesions, the N- acetyl aspartate continued to decrease, while choline and creatine concentrations
remained stable during that time. This dog was euthanized 18 month after the end of RT due to relapse.
One dog was lost to follow up 12 month after completion of RT. The other 3 dogs are still alive at the
time of writing. RT with 30 Gy in 10 fractions can provide an additional option for anti-inflammatory
treatment of focal and multifocal MUO. The protocol used for treatment monitoring was feasible while
no side effects of RT could be observed during the follow up period. Moreover, H-1 MRS could repre-
sent a new and non-invasive tool to control the progression of the disease during the treatment course.
Keywords: Meningoencephalitis, Granulomatous, Necrotizing, Leukoencephalitis, Radiation, MRI, H-1
MRS, Dog Eine Vielzahl unterschiedlicher Behandlungsoptionen der Meningoencephalitis unbekannter
Ursache des Hundes wurde in der Literatur beschrieben. Ein Goldstandard für die Therapie ist derzeit
nicht bekannt. In dieser prospektiven Studie wurden Hunde mit fokaler oder multifokaler Form der
Meningoencephalitis unbekannter Ursache mit einem neuen Strahlentherapieprotokoll von 30 Gray und
Prednisolone behandelt. Das Ziel der Studie war es den Behandlungserfolg mittels klinischer, konven-
tioneller Magnetresonanztomograhischer und Protonen Magnetresonanzspektroskopischer Verlaufsunter-
suchungen zu dokumentieren und das Auftreten mögliche Strahlentherapie bedingter Nebenwirkungen
zu erfassen. Sechs Hunde (3 mit fokaler und 3 mit multifokaler Form) wurden im Zuge dieser Studie
mit 30 Gray (aufgeteilt in 10 Fraktionen)behandelt. Der neurologische Status aller 6 Hunde hat sich
unter Strahlentherapie verbessert, wobei 3 der 6 Hunde eine komplette Erholung zeigten. Ein Hund
wurde innerhalb der ersten 3 Wochen nach Ende der Bestrahlungstherapie eingeschläfert. Die Kontroll
–Magnetresonanztomographie nach 3 Monaten war normal bei einem Hund und zeigte Verbessereungen
bei 3 weiteren Hunden. Auch die Protonen Magnetresonanzspektroskopie zeigte eine Normalisierung in
diesen 4 Fällen. Der fünfte Hund zeigte keine Verbesserung in der Bildgebung. Dieser Hund musste nach
18 Monaten eingeschläfert werden. Bei einem weiteren Hund konnte der Verlauf nur 12 Monate nachver-
folgt werden, die anderen 3 Hund sind zum Zeitpunkt des Verfassens der Publikation noch am Leben und
ohne Anzeichen eines Rückfalls. Bestrahlungstherapie mit 30 Gray aufgeteilt in 10 Fraktionen ist eine
zusätzliche Behandlungsoption für die Meningoencephalitis unbekannter Ursache des Hundes. Das Pro-
tokoll das zur Verlaufskontrolle durchgeführt wurde war realisisbar und es konnten keine Nebenwirkungen
der Strahlentherapie dokumentiert werden. Zusätzlich zeigt die Studie, dass Protonen Magnetresonanz-
tomographie eine neue und nichtt-invasive Methode zur Überwachung der Progression der Erkrankung
unter Therapie darstellen könnte. Schlüsselwörter: Meningoencephalitis, Bestrahlungstherapie, Magne-
tresonanzspektroskopie
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Summary 
A plethora of treatment options have been described for canine meningoencephalitis of 
unknown origin (MUO), yet a gold standard has not been established. The aim of this 
prospective pilot study was to document the effect of a newly designed 30 Gray (Gy) 
radiation therapy (RT) protocol plus corticosteroids as treatment for focal and multifocal 
MUO, to monitor clinical and imaging changes during the course of the disease with 
conventional magnetic resonance imaging (MRI) and proton MR Spectroscopy (H-1 MRS) 
and to detect the occurrence of radiation related side effects. Six dogs were included in the 
study. The RT protocol used consisted of 30 Gy in 10 fractions. The neurological status of all 
six dogs improved during RT, with 3 of 6 cases returning to a normal condition. One dog was 
euthanized early during follow-up (<3 weeks after end of RT). Three month follow up MRI 
was normal in one dog and improved in 3 dogs and H-1 MRS normalized in 4. In the dog 
without improvement of the MRI lesions, the N-acetyl aspartate continued to decrease, while 
choline and creatine concentrations remained stable during that time. RT with 30 Gy in 10 
fractions can provide an additional option for anti-inflammatory treatment of focal and 
multifocal MUO. The protocol used for treatment monitoring was feasible while no side 
effects of RT could be observed during the follow up period. Moreover, H-1 MRS could 
represent a new and non-invasive tool to control the progression of the disease during the 
treatment course. 
Keywords: Meningoencephalitis, Granulomatous, Necrotizing, Leukoencephalitis, Radiation, 
MRI, H-1 MRS, Dog 
 2
Zusammenfassung 
Eine Vielzahl unterschiedlicher Behandlungsoptionen der Meningoencephalitis unbekannter 
Ursache des Hundes wurde in der Literatur beschrieben. Ein Goldstandard für die Therapie 
ist derzeit nicht bekannt. In dieser prospektiven Studie wurden Hunde mit fokaler oder 
multifokaler Form der Meningoencephalitis unbekannter Ursache mit einem neuen 
Strahlentherapieprotokoll von 30 Gray und Prednisolon behandelt. Das Ziel der Studie war 
es, den Behandlungserfolg mittels klinischer konventioneller magnetresonanztomograhischer 
und Protonen magnetresonanzspektroskopischer Verlaufsuntersuchungen zu dokumentieren 
und das Auftreten möglicher Strahlentherapie bedingter Nebenwirkungen zu erfassen. Sechs 
Hunde (3 mit fokaler und 3 mit multifokaler Form) wurden im Zuge dieser Studie mit 30 
Gray (aufgeteilt in 10 Fraktionen) behandelt. Der neurologische Status aller 6 Hunde hat sich 
unter Strahlentherapie verbessert, wobei 3 der 6 Hunde eine komplette Erholung zeigten. Ein 
Hund wurde innerhalb der ersten 3 Wochen nach Ende der Bestrahlungstherapie 
eingeschläfert. Die Kontroll – Magnetresonanztomographie nach 3 Monaten war bei einem 
Hund normal und zeigte bei 3 weiteren Hunden Verbesserungen. Auch die Protonen 
Magnetresonanzspektroskopie zeigte eine Normalisierung in diesen 4 Fällen. Der fünfte 
Hund zeigte keine Verbesserung in der Bildgebung. Dieser Hund musste nach 18 Monaten 
eingeschläfert werden. Bei einem weiteren Hund konnte der Verlauf nur 12 Monate verfolgt 
werden, die anderen 3 Hunde sind zum Zeitpunkt des Verfassens der Publikation noch am 
Leben und ohne Anzeichen eines Rückfalls. Bestrahlungstherapie mit 30 Gray aufgeteilt in 
10 Fraktionen ist eine zusätzliche Behandlungsoption für die Meningoencephalitis 
unbekannter Ursache des Hundes. Das Protokoll, das zur Verlaufskontrolle durchgeführt 
wurde, war realisierbar und es konnten keine Nebenwirkungen der Strahlentherapie 
dokumentiert werden. Zusätzlich zeigt die Studie, dass die Protonen 
Magnetresonanztomographie eine neue und nicht-invasive Methode zur Überwachung der 
Progression der Erkrankung unter Therapie darstellen könnte 
 
Schlüsselwörter: Meningoencephalitis, Bestrahlungstherapie, Magnetresonanzspektroskopie  
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Background 
Meningoencephalitis of unknown origin (MUO) is a term used for ante-mortem presumptive 
diagnosis of non-infectious meningoencephalomyelitis lacking definitive histopathological 
confirmation [1-4]. MUO includes a heterogeneous group of diseases with a suspected 
aberrant immune response directed against the central nervous system such as granulomatous 
meningoencephalitis (GME) [5-8], necrotizing meningoencephalitis (NME) [9], and 
necrotizing leukoencephalitis (NLE) [10,11]. The aetiology of these diseases is still 
unknown; however, a multitude of causes, such as neoplastic, genetic, autoimmune, 
infectious and toxic causes have been hypothesised but have not yet been proven [12-16]. 
Diagnostic imaging, in particular magnetic resonance imaging (MRI), plays an important role 
in the diagnosis of meningoencephalitis and the radiological features of this disease have 
been extensively reported in veterinary medicine [2,17-20]. However, MRI does not provide 
a definitive diagnosis, which is only achieved by histopathology. Proton magnetic resonance 
spectroscopy (H-1 MRS) is a non-invasive technique, which allows the determination of 
metabolites in living tissue [21]. H-1 MRS detects several metabolites in the normal brain, 
such as N-acetyl aspartate (NAA), choline (Cho), and creatine (Cr). NAA is considered a 
neuronal marker, and it is present only in neurons, axons and dendrites. Cho is involved in 
membrane synthesis and degradation, and Cr is involved in energy metabolism. Under 
pathological conditions these metabolites may show abnormal concentration (either absence, 
reduced or increased concentration); and other metabolites, normally not present in a healthy 
brain (such as lipids or lactate) may be evident [22,23]. H-1 MRS has been used to 
distinguish neoplastic from inflammatory disease in human patients [24,25] and has proven 
useful in monitoring the evolution of inflammatory processes such as multiple sclerosis [26]. 
The use of H-1 MRS in the brain of healthy dogs has been recently published [27,28]. It has 
also been used in research dogs for tumour models [29,30]. However, the clinical use of H-1 
MRS in dogs with meningoencephalitis has so far not been described. 
Various treatment options have been described for MUO, however a gold standard has not 
yet been established. In a recent meta-analysis [3] including 457 dogs from 71 studies, the 
authors were unable to identify a preferred immunosuppressive regimen. Radiation therapy 
(RT) protocols with total dosage ranging from 40–49.5 Gy, divided in fractions of 2.4 to 4.0 
Gy in combination with corticosteroids have been described [31,32], leading to longer mean 
survival time in dogs with focal forebrain signs compared to corticosteroid monotherapy [31]. 
However, dogs with focal signs were not preferentially selected in the study of Munana et al. 
[31], only one dog with multifocal clinical signs was included in the RT group and this dog 
was euthanized one day after completing the RT. Sission et al. described a possible early 
delayed radiation reaction in one dog that received a whole brain RT protocol with 49.5 Gy in 
15 fractions [32]. 
The aim of this prospective pilot study was to document the effect of a newly designed 30 Gy 
RT protocol applied in 10 fractions plus immunosuppressive dosage of corticosteroids as 
treatment for focal and multifocal MUO to monitor the clinical and the imaging changes 
during the course of the disease using MRI as well as H-1 MRS and to detect the occurrence 
of radiation related side effects. 
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Materials and methods 
Dogs recruited for this study were diagnosed with MUO between January 2012 and June 
2013 in the Neurology Service of the Small Animal Department, Vetsuisse-Faculty, 
University of Zurich, Switzerland. Inclusion criteria included: (1) evidence of focal or 
multifocal brain lesions during the neurological examination without signs of spinal cord 
lesions or lesions in the peripheral nervous system; (2) abnormal cerebrospinal fluid (CSF) 
(reference interval: < 5 whit blood cells (WBCs)/µL, total protein < 0.3 g/L); (3) negative 
tests for infectious diseases in the CSF (4) evidence of focal or multifocal intra-axial lesions 
in MRI, according to previously reported features [2,17-20]; (5) H-1 MRS of the brain; (6) 
follow-up MRI, H-1 MRS, and CSF-centesis following the completion of and 3 months after 
RT; (7) during the RT and follow up period, no treatment with any other immunosuppressive 
medication beside prednisolone. For all patients, owner’s informed consent was obtained for 
treatment and follow-up. The official Animal Welfare Officer of the university approved the 
study design. 
Diagnosis 
All dogs underwent thorough general examination and neurological evaluation performed 
either by a board-certified neurologist or by a neurology resident. In order to quantify the 
neurological changes of the patients during treatment and follow-up period, a neurodisability 
score (NDS) as described by Smith et al. [33] (Table 1) was applied at the time of initial 
presentation. Serum biochemical analysis and complete blood cell count were performed in 
all dogs. CSF was collected from the cisterna cerebellomedullaris and nucleated cell count, 
cytological examination and total protein (TP) concentration were determined. Tests 
performed to rule out infectious diseases included the following: a) polymerase chain reaction 
Table 1 Neurodisability score as described by Smith et al. [33] 
Cranial nerves   Mentation  Postural Responses  
PLR abnormal unilateral 0.5 Coma 1 Ataxic; ambulatory 1 
bilateral 1 Obtunded 1 Ataxic; nonambulatory 2 
Menace response abnormal unilateral 0.5 Circling/head pressing 2 Unable to stand 3 
bilateral 1     
Strabismus  1 Seizures  Paresis  
Nystagmus  1 Isolated 1 Paretic; ambulatory 1 
Head tilt  1 Clusters 2 Paretic; nonambulatory 2 
Facial paralysis unilateral 1 Status Epilepticus 3 Plegia 3 
bilateral 0.5     
Absent gag reflex  1     
Dropped jaw  2     
Megaoesophagus  2     
(PCR) from CSF for Toxoplasma gondii and Canine distemper virus (Clinical Laboratory of 
the Vetsuisse Faculty University of Zurich), b) real time PCR from CSF for Neospora 
caninum (Laboklin GMBH und co KG Bad Kissingen, Germany), c) European tick born 
encephalitis serology from serum, and CSF ELISA (enzyme linked immunosorbent assay) 
(Alomed Randolfzell –Böhringen, Germany). 
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Diagnostic imaging 
MRI of the brain was performed with a 3 T MRI scanner (Philips Ingenia scanner, Philips 
AG, 8027 Zurich, Switzerland). Conventional images included T1-weighted (dorsal, sagittal, 
transverse), T2-weighted (dorsal, sagittal, transvers), FLAIR (transverse) and T1-weighted 
(dorsal, sagittal, trasverse), after contrast medium (Gadodiamid (Omniscan®), 0.3 mmol/kg, 
GE Healthcare AG, 8152 Glattbrugg, Switzerland). H-1 MRS comprised single voxel 
localization technique, acquiring Point-Resolved Spectroscopy (PRESS) with long and/or 
short echo-time (144 and 35 respectively). The single voxel was applied in the center of the 
main lesion, avoiding contamination with CSF and bony structures. Whenever possible, 
another single voxel was performed in the presumed normal contralateral aspect of the brain, 
used for comparison. When this was not possible (because of a diffuse lesion, lesion with 
considerable mass effect to the contralateral side, or lesion in the midline), database (using 
the same spectroscopy technique) obtained in our institution from normal healthy dogs was 
used. 
A board certified non-blinded radiologist analysed the following features from the MRI 
studies: (1) number of lesions (focal, multifocal), (2) location, (3) margination (ill-defined, 
well-defined), (4) signal intensity pattern in all sequences compared to normal gray matter 
(hyperintense, hypointense or isointense), (5) contrast enhancement (degree: mild (defined as 
faintly identifiable signal increased to surrounding tissue in T1W post-contrast images), 
moderate (defined as easily identifiable signal increased to surrounding tissue in T1W post-
contrast images), severe (defined as pronounced signal increased to surrounding tissue in 
T1W post-contrast images); pattern: homogeneous, heterogeneous, rim enhancement), (6) 
presence or absence of perilesional oedema and its extent (mild (defined as faintly 
identifiable T2W and FLAIR hyperintense signal surrounding the lesions), moderate (defined 
easily identifiable T2W and FLAIR hyperintense signal surrounding the lesions), severe 
(defined as readily visible T2W and FLAIR hyperintense signal well beyond the margins of 
the lesion) (7) presence or absence of mass effect. 
LCModel software (LCModel, version 6.3, S Provencher, Oakville, ON, Canada. Automatic 
quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed 2001;14:260–264.) 
was used to analyse the MRS data obtained. The following metabolites were included in this 
study: NAA (NAA, the sum of N-acetyl aspartate and N-acetylaspartylglutamate), total 
choline (tCho, predominantly glycerophosphocholine and phosphocoline, and creatine (Cr, 
the sum of creatine and phosphocreatine). Lactate and lipids were noted if present. Metabolite 
ratios compared to creatine were used: NAA/Cr, Cho/Cr, Cho/NAA. The results in the 
abnormal and presumed normal area of the brain were compared. 
Treatment 
Radiation therapy 
Treatment planning was performed on the basis of a three-dimensional computertomography 
(CT). For treatment planning the Eclipse External Beam Planning system version 10.0 
(Varian Oncology Systems, Palo Alto, USA) was used, applying the AAA-algorithm (version 
10.0.28). For planning CT and daily treatment, patients were under general anaesthesia, 
positioned in sternal recumbency, and immobilized in an individually shaped vacuum cushion 
(BlueBag BodyFix, Elekta AB, Stockholm, Sweden) and a custom-made bite block. The 
clinical target volume (CTV) (whole brain or lesion) was delineated on the CT and extended 
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by 2 mm to define the planning target volume (PTV). Organs at risk were segmented (eyes). 
The prescribed dose was 30 Gy, delivered over two weeks in 10 daily fractions of 3 Gy to the 
ICRU reference point. Radiation was given by a Clinac iX (Varian Medical Systems, Palo 
Alto, USA). All 3D conformal radiation therapy (3DCRT) plans were calculated with 6 MV 
photons and consisted of five fields. Treatment was performed isocentrically with bolus and 
wedges to insure dose homogeneity. For some patients intensity modulated treatment (IMRT) 
was planned and delivered. The treatment was administered as image guided radiotherapy 
(IGRT) with daily orthogonal kV-imaging or cone beam CT (CBCT). Prior to treatment, all 
IMRT plans were dosimetrically verified using an Octavius®-Phantom (PTW Freiburg, 
Germany). All dogs received steroids during RT. The dosage was tapered depending on 
clinical signs (Table 2). 
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Follow-up examinations 
Follow-up 
Clinical examination and the NDS were applied at the time of initial presentation and 
repeated before starting RT, after the last radiation treatment and followed by examinations at 
3, 6, 9 and 12 month after RT. All follow-up examinations were performed by one of the 
authors (KB). Follow-up MRI and H-1 MRS and CSF tap were performed after the last RT 
and 3 months thereafter. Long term survival from beginning of RT to time point of writing 
this study was documented. 
Results 
Seven dogs were enrolled prospectively in the study. One was later excluded because post 
mortem examination was compatible with viral encephalitis; however immunohistochemistry 
failed to demonstrate presence of the endemic viral disease causing encephalitis (canine 
adenovirus, parvovirus, canine distemper virus, European tick-borne encephalitis virus) and 
of rabies virus. The remaining 6 dogs included a French bulldog, a Pug, a Lagotto 
Romagnolo, a Weimaraner, a mixed breed and a Chihuahua. Three were spayed female and 3 
were males (1 castrated and 2 sexually intact). Age at initial presentation ranged from 9 
months to 13 years (mean 4 years, median 2 years). General clinical examination was 
unremarkable in all 6 dogs. 
Before radiation therapy 
The range of the NDS at initial presentation was variable and all dogs had received steroid 
treatment prior to RT (Table 2). One dog was treated additionally with cytosine arabinoside 
(50 mg/m2 q 12 h for 2 d), but the dogs neurological status worsened and it showed side 
effects due to steroid treatment (polyuria-polydipsia, panting, alopecia and muscle weakness). 
RT was then offered as an alternative treatment. Cytosine arabinoside was not repeated and 
instead RT was started 56 days after the initial presentation (50 days after cessation of 
cytosine arabinoside). Before performing the planning CT, while the dog was free of any 
other immunosuppressive drug apart from steroids, a new complete study (MRI, H1- MRS 
and CSF tap) was performed. Only the latter results were included in the present prospective 
study and were then compared to those performed during the planned follow up. 
The first RT was applied 3 to 56 days after starting the medical treatment (mean 19.5 days, 
median 13 days). Medical treatment before the first radiation treatment resulted in an 
improved NDS in three dogs, a worsened NDS in two (including the dog previously treated 
with cytosine arabinoside) and an unchanged NDS in one. The detailed dosages of 
prednisolone, CSF examinations results, and NDS are summarized in Table 2. MRI findings 
revealed 3 dogs with focal and 3 with multifocal lesions (Table 3). 
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Table 3 Summary of the MRI findings before treatment of 6 dogs with 
meningoencephalitis of unknown origin, divided into dogs with focal and multifocal 
lesions 
 Multifocal lesions (n = 3) Focal lesions (n = 3) 
Location White and grey matter frontal, parietal and occipital lobe, with thalamic 
involvement (1) 
Brain stem to ventro-medial thalamus 
(2) 
White matter occipital lobe and optic nerve (1) Cerebellar hemisphere (1) 
Corpus nucleus caudatus and temporal lobes (1) Parietal white matter (1) 
Margination Ill-defined (3) Ill-defined (3) 
Signal intensity T2W and FLAIR hyperintense (3) T2W and FLAIR hyperintense (3) 
T1W hypointense (3) T1W hypointense (2) 
T1W isointense (1) 
Contrast 
enhancement 
Mild and heterogeneous (3) Moderate heterogenous (2) 
Moderate homogeneous (1) 
Perilesional edema Mild (2) Mild (1) 
Moderate (1) Moderate (2) 
Mass effect Present (3) Present (3) 
H-1 MRS in all cases revealed low concentration of NAA when compared to the non-affected 
contralateral side of the brain (Figures 1, 2 and 3). The choline was either unchanged (2 
cases, example Figure 1) or mildly increased (4 cases, example Figure 2). Lipids peaks were 
observed in 3 cases in the affected area (Figures 1 and 2), one of those also had a lactate peak 
(Figure 1). Lactate was detected in one additional case. The creatine peak tended to be rather 
similar in affected and non-affected sides, or very mildly reduced. All metabolite ratios 
before and after treatment are summarized in Table 4. 
Table 4 Summary of the H-1 MRS findings of 6 dogs with meningoencephalitis of 
unknown origin treated with radiotherapy, before, immediately after treatment and 3 
month follow-up 
Dogs MRS before treatment MRS after treatment MRS follow-up after 3 months 
 NAA/Cr Cho/Cr Lips/Lac NAA/Cr NAA/Cho Lips/Lac NAA/Cr Cho/Cr Lips/Lac 
 A N A N A N A N A N A N A N A N A N 
1 0.9 1.2 0.3 0.26 - - 1.1 1.2 0.28 0.26 - - - - - - - - 
2 0.65 1.2 0.35 0.312 - - 0.80 1.2 0.30 0.32 - - 1.1 1.2 0.33 0.34 - - 
3 0.52 1.31 0.56 0.34 Lac - 0.41 1.29 0.59 0.34 - - 0.23 1.3 0.58 0.33 - - 
4 0.44 1.2 0.37 0.386 Lips - 1.2 1.15 0.36 0.37 - - 1.2 1.2 0.34 0.34 - - 
Lac 
5 0.52 1.12 0.6 0.32 Lips - 0.83 1.2 0.45 0.3 - - 1.1 1.2 0.4 0.33 - - 
6 0.45 1.09 0.49 0.33 - - 0.67 1.0 0.40 0.35 - - 0.9 1.0 0.32 0.34 - - 
CSF pleocytosis was present in 5 out of 6 dogs (range: 5–134 WBCs/µL reference interval: < 
5 WBCs/µL) and protein concentration was elevated in all dogs (range: 0.37 -1.41 g/L 
reference interval: < 0.3 g/L). 
Radiation therapy 
In all but one dog, the whole brain was considered as CTV (median volume 73.2 cm3, mean 
59.8 cm3, range 1.1-80.6 cm3). The median dose to the PTV was 30.4 Gy (mean 30.4 Gy, 
range 27.6-31.4 Gy). Two patients were treated with an IMRT plan, as dose to organs at risk 
(eyes) was lower, while 3 patients had a regular 3D conformal RT (3DCRT)-plan. The 
median dose to the organs at risk (left and right eye) was 10.4 and 10.8 Gy (mean 10.5 Gy, 
range 0.1-16.5 and 10.8 Gy, range 0.1-16.9 Gy, respectively). Overall treatment time was 14 
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days (mean; range 12–16 days) and time to start of treatment after diagnosis was 17 days 
(mean; range 3 – 56 days). 
Follow-up immediate after treatment 
The NDS was normal in 3 dogs (2 dogs with focal lesion, one with multifocal), improved in 2 
dogs (one with focal, one with multifocal lesion) and unchanged in one dog (multifocal 
lesion) compared to the initial presentation and also before start of RT. All dogs included in 
this study had MRI follow-up immediately after the last session of RT. MRI showed marked 
reduction of the perilesional oedema in all cases. Mass effect was improved in 5 out of 6 
dogs. One patient with a focal lesion in the brain stem showed complete resolution after RT 
(Figure 3). Two dogs with focal lesions showed a decrease in size of the lesion (Figure 4). In 
the dogs with multifocal disease, two had improvement and reduction in size of the lesions; 
while in one dog with multifocal disease the lesions were not improved (Figure 5). The signal 
intensity pattern of the remaining lesions in all dogs after treatment was the same as before 
treatment. No new abnormalities were observed in any of the patients included in this study. 
 
Three-month follow-up 
Five dogs were re-examined 3 months later. None of these dogs received steroids at that time 
point. The three dogs with the focal lesions on MRI and one of the dogs with multifocal 
lesions had a completely normal neurological examination and a NDS of 0. One of these dogs 
that initially presented due to seizures was free of seizures after therapy without concurrent 
antiepileptic treatment. The other dog with the multifocal lesions still showed unilateral 
menace response deficit and unilateral reduced proprioception, but was free of seizures 
during the 3 months of observation (NDS 1). This dog continued on antiepileptic medication 
(Phenobarbital 2.5 mg/kg BID, Levetiracetam 20 mg/kg three times daily (TID)) due to 
severe seizure activity before therapy. Serum levels of phenobarbital were checked 3 weeks 
after the beginning of the treatment and repeated every 3 months. Serum concentration was 
always within the therapeutic range. 
MRI revealed improvement of the lesions (however, not complete resolution) in 4 out of 5 of 
the cases. No new lesions were found. MRS showed complete recovery of the Cho and NAA 
concentration, being equal to the contralateral side in 4 out of 5 dogs. In the dog without 
improvement of the MRI lesions, the NAA continued to decrease, while Cho and Cr 
concentrations remained stable during that time. 
CSF analysis demonstrated a slight or moderate increase in total protein (0.33 g/l and 0.45 
g/l, respectively) in 2/5 dogs. 
Long-term outcome 
Five dogs had additional clinical follow-up examinations every 3 months for 9 (n = 1), 12 (n 
= 3) and 18 (n = 1) months after RT. Three dogs were neurologically normal in all follow-up 
examinations. One dog had one single seizure episode and one dog continued to have 2–3 
seizures per month despite the use of antiepileptic medical treatment and the neurological 
deficits noticed at the 3 months follow-up were still present. This dog had a relapse 18 
months after the end of RT, which was confirmed by MRI and CSF tap. The dog did not 
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respond to prednisolone (4 mg/kg SID for 2 days, followed by 3 mg/kg) and cyclosporine (6 
mg/kg BID) treatment and was euthanased 3 weeks later. The owner declined necropsy. The 
owners of the 4 other dogs were contacted by telephone: one dog was lost to follow-up after 
12 months, the other 3 dogs were still alive and according to the owners remained clinically 
normal at the time of writing (12, 21 and 26 months after RT). Neither early nor late onset of 
RT reactions could be detected in our study population and owners described the whole RT 
plan as satisfactory and without any relevant complications. 
In all patients we were always able to record good quality spectra from both the diseased and 
from the non-affected sites. All the acquired spectra were successfully studied further using 
the LC Model. 
Discussion 
This pilot study shows that the 30 Gy ionizing RT combined with immunosuppressive dosage 
of corticosteroids is a feasible protocol that can be considered as a therapeutic option not only 
in dogs with focal but also in dogs with multifocal MUO. Furthermore we showed that H-1 
MRS could be applied to strengthen the clinical suspicion achieved by means of combined 
data arising from clinical and neurological examination, CSF-centesis, conventional MRI and 
to monitor the disease course during the treatment of MUO. 
The survival time in our study (median of 476 days) is in accordance with the findings by 
Munana et al. [31], who found that six out of seven dogs with GME treated with radiotherapy 
had a survival time of > 250 days with a median of 404 days. Munana et al. [31] included 
mainly dogs with focal GME. Only one dog with multifocal clinical signs was enrolled in that 
study and was treated with RT. It was euthanased immediately after the completion of RT 
due to a lack of clinical response. In our study, we included dogs with MRI features of focal 
and multifocal MUO. All our patients with focal MUO responded favourably to RT treatment 
similarly to those from the study of Munana et al. [31]. In contrast to the only study about RT 
in focal GME patients, we were able to follow patients clinically and radiologically up to 26 
months. Similar to Munana et al. [31] all our dogs received steroids during the study period. 
But since neither the exact dosage nor the duration of treatment is described in their paper, 
we cannot compare the effect of this add-on treatment for both studies. The same holds true 
for most studies about medical treatment of MUO. In one study prednisolone monotherapy 
(11 dogs) was compared to prednisolone in combination with Lomustine (14 dogs) [34]: 
within the first 12 months of treatment, the dosage of prednisolone was decreased from 1.4 to 
0.6 mg/kg/d compared to a dosage reduction from 2.1 to 0.2 mg/ kg/d in dogs treated with 
both. In only 4 dogs (all Lomustine group) could the prednisolone be discontinued in that 
study and in only one dog were the steroids discontinued after 3 months [35]. In one report 
about NME in 7 dogs treated either with prednisolone alone or in combination with 
cyclosporine [36], the 4 dogs receiving both medications prednisolone were started with 1 
mg/kg twice daily (BID), reduced after two weeks to 0.75 mg/kg and after another 2 weeks 
reduced to the final dosage of 0.5 mg/kg BID. In the dogs with monotherapy steroid dosage 
was not reduced. In a more recent study [20] prednisolone was used in combination with 
cytosine arabinoside for treatment of MUO: the initial dosage of 1 mg/kg BID was 
completely tapered over 34 weeks. The dosage after 3 months was 0.25 mg/kg BID. In only 
one case series, prednisolone was completely replaced by cyclosporine within 2 weeks in 
dogs with suspected GME. In comparison to these results, the steroids in our dogs were all 
discontinued within 3 months after the beginning of RT. 
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The MRI findings in this study agree with previously reported findings [2,17-20]. Lowrie et 
al. [20] studied the prognostic factors and outcome of dogs with MUO. These authors showed 
that MRI resolution of lesions at three months are indicative of a good outcome, but not 
predictive of relapse, whilst abnormal CSF at three months was associated with higher risk of 
relapse. They concluded that the best prognostic factors were a combination of repeated MRI 
and CSF analysis, with resolution of both at three months suggesting a good or excellent 
long-term outcome. Only one dog in our study had complete MRI resolution of the lesions 
previously seen over 3 months. However, H-1 MRS showed in 5 cases that the NAA 
recovered over time while the choline concentration decreased and lipids were not present 
anymore. These findings parallel the improvement on the clinical status and the CSF analysis 
in four out of five dogs. Decreased levels of NAA are well documented in people with 
inflammatory lesions, such as multiple sclerosis [24,37]. The reduction of NAA in acute 
lesions may be caused by oedema, transient neuronal impairment or loss [24]. NAA can show 
a dynamic behaviour over time as it may recover to remyeliniation [24,37] or attributed to 
therapy in viral diseases [38]. In people a decrease of NAA correlates well with increasing 
neurological disability and worsening clinical state [39]. Choline is reported to be mildly to 
moderately elevated in acute demyelination due to alteration of the cell membranes and due 
to increased membrane turnover in viral diseases. These findings may recover to normality 
during the follow-up after acute events in multiple sclerosis [37], or may increase during the 
progress of viral disease [38]. The presence of lipids is attributed to membrane breakdown, 
when fractured lipids become spectroscopically visible. Lactate is related to anaerobic 
glycolysis of the brain or macrophage activation after membrane breakdown [13,15]. In this 
scenario, the changes seen in our patients corresponded to inflammatory white matter disease 
in people. Furthermore, the follow-up studies allowed us to demonstrate the recovery of NAA 
(and decrease of Cho in some cases), which can be correlated, with the improvement of the 
clinical signs and neurodisability score. 
This is the first report of dogs with MUO in which H-1 MRS is used as a diagnostic and 
monitoring tool. Several authors have acknowledged the need of a non-invasive test for the 
diagnosis of MUO [2,20,34]. The preliminary results of this pilot study show that H-1 MRS 
is a feasible technique and provides additional information for the diagnosis of MUO and it is 
a valuable tool for monitoring the disease. Further studies with larger number of patients are 
necessary to assess its validity as a prognostic factor. 
H-1 MRS is also used to evaluate the potential changes of normal brain tissue caused by 
radiotherapy [40-42]. At the three-month follow-up, we did not observe any change in the 
normal contralateral side in any dog. In this study no relevant side effects of RT could be 
detected during the observation period. The fractionation schedule of 30 Gy in 10 fractions is 
considered to be standard for human patients with whole brain radiation due to metastatic 
disease. With the used protocol of 30 Gy in 10 fractions the late toxicity such as radiation-
induced dementia is estimated to be 1.9%-5.2% for human patients treated with brain 
metastasis, and is not high enough to warrant withholding quality of life prolonging whole 
brain RT [43]. 
A potential downside of this treatment protocol is the need for repeated general anesthesia for 
RT and CSF collection. However, this is an inevitable part of this treatment protocol and we 
were not aware of any detrimental effects in the present study. The risk of complications due 
to the daily short and mild anaesthesia can be considered low; no increased risks for dogs 
with intracranial neoplasia undergoing RT have been reported in the literature. 
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A number of limitations are associated with this pilot study. This study was not designed to 
assess the superiority of the 30 Gy RT protocol against another treatment. Moreover the low 
number of dogs included and the lack of a control group treated only with corticosteroids or 
with other drugs highlights the need for further evidence-based studies. Therefore, we cannot 
prove how much of the observed improvement in our patients was due to steroid treatment or 
was a result of the RT or a combination of both. To achieve this, a larger randomized, 
blinded, superiority study is needed to draw meaningful conclusions. Another limitation of 
the study is that the radiologist was not blinded to the clinical signs. However, the diagnosis 
of MUO should be a combination of the knowledge of the clinical signs, MRI and CSF 
findings. Histological confirmation before initiation of treatment might be advocated as the 
“condicio sine qua non” in order to design more informative studies about treatment of 
MUO. The possible complications [44], owners concerns, and technical difficulties (such as 
sampling vulnerable anatomical location or achieving a definitive diagnosis) are important 
drawbacks. Biopsy was strongly suggested to the owners of all our patients but none agreed 
to the procedure. Therefore we concur with Granger et al. [3] that the definition of inclusion 
criteria based upon clinical characteristics alone is important in order to include a high 
number of dogs in such studies. 
Conclusions 
RT with a total dosage of 30 Gy in combination with corticosteroids is a feasible potential 
additional option for the treatment of MUO compared to previously published protocols. A 
randomized, prospective study, comparing outcome after RT and medical treatment, will be 
the next step to approve the clinical validity of RT. Furthermore, H-1 MRS is a promising 
non-invasive technique also in veterinary neuroradiology that provides very useful 
biochemistry information and might be used in the future as a tool for assessing prognostic 
factors and treatment effectiveness. 
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Figure 1 Pre-treatment MRI (A and C, T2W sequences, transverse and dorsal 
respectively) and pre-treatment H-1 MRS (B and D, single voxel PRESS-144 on the 
normal and abnormal brain respectively; the red squares highlight where the voxel was 
located), of a Weimaraner dog with focal MUO affecting the left thalamus extending to 
the mesencephalon. In A and C an ill-marginated hyperintense lesion is seen, causing mild 
mass effect. When comparing B and D, it can be appreciated a clear reduction of the NAA 
peak, mild increase of Cho and the presence of lactate and lipids in the affected side. 
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Figure 2 Pre-treatment MRI (A and C, T2W transverse) and pre-treatment H-1 MRS 
(B and D, SV PRESS-35 on the abnormal and contralateral presumed normal area of 
the brain (the red squares highlight where the voxel was located) of a mixed breed dog 
with focal MUO affecting the left parietal lobe. Notice in A and C the ill-defined 
hyperintense lesion, with moderate perilesional oedema and moderate mass effect 
compressing the left lateral ventricle. B shows mild elevation of the Cho peak, decrease of 
the NAA peak, and presence of lipids in the affected area 
 20
 
Figure 3 The Weimaraner of Figure 1 just after radiotherapy treatment (A: transverse 
T2W, B: PRESS 144 normal side; C: dorsal T2W; D: PRESS 144 abnormal side). The 
H-1 MRS single voxels were positioned at the same areas as pre-treatment. Notice the 
complete resolution of the lesion previously described affecting the left thalamus extending to 
the mesencephalon (A and C). The spectrum of the normal (B) and previously abnormal 
region (D), are now very comparable, revealing a recovery of the neurons. 
 21
 
Figure 4 The mixed breed of Figure 2 after radiotherapy treatment (A and B: 
transverse T2W, C: H-1 MRS single voxel PRESS 35 of the left temporal lesion). Notice 
in A and B a reduction in size of the lesion, as well as improvement of the perilesional 
oedema and mass effect when compared to pretreatment images of Figure 2. However, the 
lesion was not yet resolved. C shows the MRS spectrum, which reveals recovery of the NAA 
peak, reduction of the Cho peak and not longer presence of lipids, when compared to pre-
treatment spectra. 
 22
 
Figure 5 H-1 MRS single voxel PRESS 144 in a Pug dog with multifocal MUO. A: 
normal side before treatment, B: abnormal side before treatment, C: abnormal side straight 
after radiotherapy treatment, D: abnormal side 3 months after. Notice the decrease of the 
NAA concentration over time, which is very marked at 3 months. 
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